195 related articles for article (PubMed ID: 36429040)
1. Label-Free Imaging Analysis of Patient-Derived Cholangiocarcinoma Organoids after Sorafenib Treatment.
Koch M; Nickel S; Lieshout R; Lissek SM; Leskova M; van der Laan LJW; Verstegen MMA; Christ B; Pampaloni F
Cells; 2022 Nov; 11(22):. PubMed ID: 36429040
[TBL] [Abstract][Full Text] [Related]
2. Protocol for inducing branching morphogenesis in human cholangiocyte and cholangiocarcinoma organoids.
Ober K; Roos FJM; van Tienderen GS; Köten K; Klaassen A; Mi W; van der Laan LJW; Verstegen MMA
STAR Protoc; 2023 Sep; 4(3):102431. PubMed ID: 37432852
[TBL] [Abstract][Full Text] [Related]
3. Patient-Derived Organoids of Cholangiocarcinoma.
Maier CF; Zhu L; Nanduri LK; Kühn D; Kochall S; Thepkaysone ML; William D; Grützmann K; Klink B; Betge J; Weitz J; Rahbari NN; Reißfelder C; Schölch S
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445380
[TBL] [Abstract][Full Text] [Related]
4. Potent in vitro and in vivo antitumor activity of sorafenib against human intrahepatic cholangiocarcinoma cells.
Sugiyama H; Onuki K; Ishige K; Baba N; Ueda T; Matsuda S; Takeuchi K; Onodera M; Nakanuma Y; Yamato M; Yamamoto M; Hyodo I; Shoda J
J Gastroenterol; 2011 Jun; 46(6):779-89. PubMed ID: 21331764
[TBL] [Abstract][Full Text] [Related]
5. Causes of hOCT1-Dependent Cholangiocarcinoma Resistance to Sorafenib and Sensitization by Tumor-Selective Gene Therapy.
Lozano E; Macias RIR; Monte MJ; Asensio M; Del Carmen S; Sanchez-Vicente L; Alonso-Peña M; Al-Abdulla R; Munoz-Garrido P; Satriano L; O'Rourke CJ; Banales JM; Avila MA; Martinez-Chantar ML; Andersen JB; Briz O; Marin JJG
Hepatology; 2019 Oct; 70(4):1246-1261. PubMed ID: 30972782
[TBL] [Abstract][Full Text] [Related]
6. 5-Aminolevulinic acid-mediated photodynamic activity in patient-derived cholangiocarcinoma organoids.
Fujiwara H; Takahara N; Tateishi K; Tanaka M; Kanai S; Kato H; Nakatsuka T; Yamamoto K; Kogure H; Arita J; Nakai Y; Kasuga M; Ushiku T; Hasegawa K; Koike K
Surg Oncol; 2020 Dec; 35():484-490. PubMed ID: 33126085
[TBL] [Abstract][Full Text] [Related]
7. Establishment of Patient-Derived Organoids and Drug Screening for Biliary Tract Carcinoma.
Saito Y; Muramatsu T; Kanai Y; Ojima H; Sukeda A; Hiraoka N; Arai E; Sugiyama Y; Matsuzaki J; Uchida R; Yoshikawa N; Furukawa R; Saito H
Cell Rep; 2019 Apr; 27(4):1265-1276.e4. PubMed ID: 31018139
[TBL] [Abstract][Full Text] [Related]
8. Effective palliation of advanced cholangiocarcinoma with sorafenib: a two-patient case report.
LaRocca RV; Hicks MD; Mull L; Foreman B
J Gastrointest Cancer; 2007; 38(2-4):154-6. PubMed ID: 19089671
[TBL] [Abstract][Full Text] [Related]
9. Clinical presentation, diagnosis and staging of cholangiocarcinoma.
Forner A; Vidili G; Rengo M; Bujanda L; Ponz-Sarvisé M; Lamarca A
Liver Int; 2019 May; 39 Suppl 1():98-107. PubMed ID: 30831002
[TBL] [Abstract][Full Text] [Related]
10. [Establishment and application of intrahepatic cholangiocarcinoma organoid models].
Liu Y; Liang X
Zhonghua Wai Ke Za Zhi; 2024 Apr; 62(4):346-352. PubMed ID: 38432677
[TBL] [Abstract][Full Text] [Related]
11. Modelling immune cytotoxicity for cholangiocarcinoma with tumour-derived organoids and effector T cells.
Zhou G; Lieshout R; van Tienderen GS; de Ruiter V; van Royen ME; Boor PPC; Magré L; Desai J; Köten K; Kan YY; Ge Z; Campos Carrascosa L; Geuijen C; Sprengers D; van der Laan LJW; Verstegen MMA; Kwekkeboom J
Br J Cancer; 2022 Sep; 127(4):649-660. PubMed ID: 35597867
[TBL] [Abstract][Full Text] [Related]
12. Mass-forming intrahepatic cholangiocarcinoma presenting tumor growth in extrahepatic bile duct and superficial spreading.
Regimbeau JM; Panis Y; Nemeth J; Pocard M; de Claviere G; Soyer P; Valleur P
Hepatogastroenterology; 2003; 50(49):21-3. PubMed ID: 12629982
[TBL] [Abstract][Full Text] [Related]
13. Sorafenib inhibits signal transducer and activator of transcription-3 signaling in cholangiocarcinoma cells by activating the phosphatase shatterproof 2.
Blechacz BR; Smoot RL; Bronk SF; Werneburg NW; Sirica AE; Gores GJ
Hepatology; 2009 Dec; 50(6):1861-70. PubMed ID: 19821497
[TBL] [Abstract][Full Text] [Related]
14. Effect of FGFR2 Alterations on Overall and Progression-Free Survival in Patients Receiving Systemic Therapy for Intrahepatic Cholangiocarcinoma.
Abou-Alfa GK; Bibeau K; Schultz N; Yaqubie A; Millang B; Ren H; Féliz L
Target Oncol; 2022 Sep; 17(5):517-527. PubMed ID: 36114955
[TBL] [Abstract][Full Text] [Related]
15. Systemic therapy for hepatocellular carcinoma and cholangiocarcinoma.
Chung V
Surg Oncol Clin N Am; 2015 Jan; 24(1):187-98. PubMed ID: 25444475
[TBL] [Abstract][Full Text] [Related]
16. Cholangiocarcinoma Disease Modelling Through Patients Derived Organoids.
Amato F; Rae C; Prete MG; Braconi C
Cells; 2020 Mar; 9(4):. PubMed ID: 32235647
[TBL] [Abstract][Full Text] [Related]
17. Effective treatment of advanced cholangiocarcinoma by hepatic arterial infusion chemotherapy combination with sorafenib: one case report from China.
Qun W; Tao Y
Hepatogastroenterology; 2010; 57(99-100):426-9. PubMed ID: 20698202
[TBL] [Abstract][Full Text] [Related]
18. Oncogenic KRAS-expressing organoids with biliary epithelial stem cell properties give rise to biliary tract cancer in mice.
Kasuga A; Semba T; Sato R; Nobusue H; Sugihara E; Takaishi H; Kanai T; Saya H; Arima Y
Cancer Sci; 2021 May; 112(5):1822-1838. PubMed ID: 33068050
[TBL] [Abstract][Full Text] [Related]
19. MET‑RON dual inhibitor, BMS‑777607, suppresses cholangiocarcinoma cell growth, and MET‑RON upregulation indicates worse prognosis for intra‑hepatic cholangiocarcinoma patients.
Cheng CT; Chen YY; Wu RC; Tsai CY; Chiang KC; Yeh TS; Chen MH; Yeh CN
Oncol Rep; 2018 Sep; 40(3):1411-1421. PubMed ID: 30015968
[TBL] [Abstract][Full Text] [Related]
20. A proposal of imaging classification of intrahepatic mass-forming cholangiocarcinoma into ductal and parenchymal types: clinicopathologic significance.
Rhee H; Kim MJ; Park YN; An C
Eur Radiol; 2019 Jun; 29(6):3111-3121. PubMed ID: 30560357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
